By Editor , 27 October 2026 Akari Files PCT Application Covering PH1 Splicing Payload Pathways TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has filed international patent application PCT/US2026/45955, adding claims on how its PH1 payload modulates alternative splicing across multiple cancer-driving genes.